CSChi-Won Suk

Chi-Won Suk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chi-Won Suk has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Antihyperglycemic Drugs and Risk of Asthma Exacerbation in Patients With Asthma and Type 2 Diabetes: A Multinational Retrospective Cohort Study

    by Chun‐Tse Hung, Chen‐Yen An, Yao‐Cheng Tsai, Chi‐Won Suk, Chung‐Hsuen Wu

    Background: Antihyperglycemic drugs have shown benefits in asthma control. However, evidence regarding the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) in reducing asthma exacerbations remains inconsistent. Objective: We aimed to evaluate the association of GLP‐1 RAs versus SGLT‐2is with risk of asthma exacerbation among patients with asthma and type 2 diabetes. Methods: This retrospective cohort study used electronic health record data from the TriNetX Global Collaborative Network. Adults with asthma and type 2 diabetes who initiated GLP‐1 RAs or SGLT‐2is between January 1, 2013, and June 30, 2024, were included. The primary outcome was the time to first asthma exacerbation. Secondary outcomes included first episode of asthma symptoms or systemic corticosteroid use. Patients were followed for up to 6 months in the main analysis. Propensity score matching was performed to balance baseline characteristics between groups. Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Results: A total of 100,746 patients were included, comprising 61,955 GLP‐1 RA users and 38,791 SGLT‐2i users. After 1:1 matching, both groups consisted of 28,831 patients. GLP‐1 RAs were associated with a decreased risk of asthma exacerbation compared with SGLT‐2is (HR, 0.88; 95% CI, 0.85–0.91). GLP‐1 RAs were also associated with a decreased risk of experiencing asthma symptoms (HR, 0.89; 95% CI, 0.82–0.97) and receiving systemic corticosteroids (HR, 0.79; 95% CI, 0.76–0.82). Results from sensitivity analyses were generally consistent, but the association for asthma exacerbation was not observed when follow‐up was extended to 1 year (HR, 0.95; 95% CI, 0.89–1.02). Conclusion: GLP‐1 RAs were associated with a decreased risk of asthma exacerbation compared to SGLT‐2is among patients with asthma and type 2 diabetes. As these findings reflect associations rather than causal effects, further investigation through randomized trials is warranted. image


  • Prevalence and characteristics in long COVID among adults with asthma in the United States

    by Chun-Tse Hung, Yu-Chien Hung, Chi-Won Suk

    The purpose of this study was to assess: (1) the prevalence of long COVID by asthma status, and (2) the characteristics associated with developing long COVID among adults with asthma in the United States. Data from the 2022 National Health Interview Survey were used. The prevalence of long COVID was reported and stratified by asthma status. The multivariable logistic regression model was conducted to identify the factors associated with developing long COVID. In 2022, the overall prevalence of long COVID among U.S. adults was 6.9%. When stratified by asthma status, the prevalence of long COVID was 13.9% among adults with asthma, and 6.2% among adults without asthma. Among adults with asthma, certain characteristics, including age over 55 years, female sex, obesity, problems paying medical bills and a history of asthma attacks, were significantly associated with developing long COVID. This study revealed that the prevalence of long COVID among adults with asthma was much higher than the general adult population in the United States. The limited validity of the collected information in this study should prompt caution when interpreting our findings. Further studies on the association between asthma and long COVID could be valuable for the clinical practice.